

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-9. (canceled)

10. (currently amended) ~~An isolated~~ A complex of a ligand and a polypeptide, wherein the polypeptide ~~comprising~~ comprises an amino acid sequence that is homologous or at least 70% identical to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60 and wherein the ligand binds to the polypeptide at the amino acid sequence that is homologous or at least 70% identical to the murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60, ~~an amino acid sequence selected from the group consisting of amino acids 32-52 of SEQ ID NO:2, amino acids 33-53 of SEQ ID NO:5, amino acids 40-60 of SEQ ID NO:7, amino acids 40-60 of SEQ ID NO:9, and amino acids 37-57 of SEQ ID NO:10,~~ with the proviso that where the a polypeptide ~~comprising~~ is a full length synaptotagmin I or II ~~is excluded,~~ the ligand is not a botulinum toxin.

11. (currently amended) The ~~complex isolated polypeptide~~ of claim ~~50~~ 10, wherein the polypeptide comprises an amino acid sequence that is at least 80% identical to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60 ~~an amino acid sequence selected from the group consisting of amino acids 32-52 of SEQ ID NO:2, amino acids 33-53 of SEQ ID NO:5, amino acids 40-60 of SEQ ID NO:7, amino acids 40-60 of SEQ ID NO:9, and amino acids 37-57 of SEQ ID NO:10.~~

12. (currently amended) The ~~complex isolated polypeptide~~ of claim ~~50~~ 10, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60 ~~an amino acid sequence selected from the group consisting of amino acids 32-52 of SEQ ID NO:2, amino acids 33-53 of SEQ ID NO:5, amino acids 40-60 of SEQ ID NO:7, amino acids 40-60 of SEQ ID NO:9, and amino acids 37-57 of SEQ ID NO:10.~~

13. (currently amended) The complex ~~isolated polypeptide~~ of claim 50 ~~10~~, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60 ~~an amino acid sequence selected from the group consisting of amino acids 32-52 of SEQ ID NO:2, amino acids 33-53 of SEQ ID NO:5, amino acids 40-60 of SEQ ID NO:7, amino acids 40-60 of SEQ ID NO:9, and amino acids 37-57 of SEQ ID NO:10.~~

14. (currently amended) The isolated polypeptide of claim 50 ~~10~~, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of ~~amino acids 32-52 of SEQ ID NO:2, amino acids 33-53 of SEQ ID NO:5, amino acids 40-60 of SEQ ID NO:7~~ and amino acids 40-60 of SEQ ID NO:9, ~~and amino acids 37-57 of SEQ ID NO:10.~~

15-40. (canceled)

41. (new) The complex of claim 10, wherein the polypeptide comprises an amino acid sequence that is identical or homologous to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60.

42. (new) The complex of claim 10, wherein the ligand is botulinum neurotoxin B, and wherein the polypeptide is a synthetic or recombinant peptide.

43. (new) The complex of claim 42, wherein the polypeptide has a sequence identical or homologous to a luminal portion of a synaptotagmin.

44. (new) The complex of claim 42, wherein the polypeptide consists of the BoNT/B-binding domain and optionally further consists of an affinity tag.

45. (new) The complex of claim 10, wherein the ligand is an antibody or a botulinum toxin fragment that binds to the BoNT/B-binding domain and reduces binding of botulinum neurotoxin B to the polypeptide.

46. (new) The complex of any one of claim 10 or claim 45, wherein the polypeptide is a full length synaptotagmin.

47. (new) The complex of claim 45, wherein the polypeptide is located *in vivo*.

48. (new) The complex of claim 10, wherein the polypeptide further comprises a binding site for a ganglioside.

49. (new) The complex of claim 10, wherein the polypeptide is a recombinant polypeptide.

50. (new) The complex of claim 10, wherein the polypeptide comprises an amino acid sequence that is at least 70% identical to a murine synaptotagmin II BoNT/B-binding domain at amino acid position 40 to 60.